Skip to main content
NCBI home page
American Journal of Human Genetics logoLink to American Journal of Human Genetics
. 1996 Nov;59(5):1048–1056.

Molecular analysis of a GM2-activator deficiency in two patients with GM2-gangliosidosis AB variant.

U Schepers 1, G Glombitza 1, T Lemm 1, A Hoffmann 1, A Chabas 1, P Ozand 1, K Sandhoff 1
PMCID: PMC1914821  PMID: 8900233

Abstract

Lysosomal degradation of ganglioside GM2 by beta-hexosaminidase A (hex A) requires the presence of the GM2 activator protein (GM2AP) as an essential cofactor. A deficiency of the GM2 activator causes the AB variant of GM2 gangliosidosis, a recessively inherited disorder characterized by excessive neuronal accumulation of GM2 and related glycolipids. Two novel mutations in the GM2 activator gene (GM2A) have been identified by the reverse-transcriptase-PCR method--a three-base deletion, AAG262-264, resulting in a deletion of Lys88, and a single-base deletion, A410, that causes a frameshift. The latter results in substitution of 33 amino acids and the loss of another 24 amino acid residues. Both patients are homoallelic for their respective mutations inherited from their parents, who are heteroallelic at the GM2A locus. Although the cultured fibroblasts of both patients produce normal levels of activator mRNA, they lack a lysosomal form of GM2AP. Pulse/chase labeling of cultured fibroblasts of the patients, in presence and absence of brefeldin A, indicates a premature degradation of both--mutant and truncated--GM2APs in the endoplasmic reticulum or Golgi. These results were supported by in vitro translation experiments and expression of the mutated proteins. When the mutated GM2APs were expressed in Escherichia coli, both mature GM2AP forms turned proved to exhibit only residual activities in an in vitro assay.

Full text

PDF
1048

Images in this article

1051Figure 2
on p.1051
1051Figure 3
on p.1051
1052Figure 4
on p.1052
1052Figure 5
on p.1052
1053Figure 6
on p.1053
1053Figure 7
on p.1053

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burg J., Banerjee A., Sandhoff K. Molecular forms of GM2-activator protein. A study on its biosynthesis in human skin fibroblasts. Biol Chem Hoppe Seyler. 1985 Sep;366(9):887–891. doi: 10.1515/bchm3.1985.366.2.887. [DOI] [PubMed] [Google Scholar]
  2. Conzelmann E., Sandhoff K. Purification and characterization of an activator protein for the degradation of glycolipids GM2 and GA2 by hexosaminidase A. Hoppe Seylers Z Physiol Chem. 1979 Dec;360(12):1837–1849. doi: 10.1515/bchm2.1979.360.2.1837. [DOI] [PubMed] [Google Scholar]
  3. Ferlinz K., Hurwitz R., Weiler M., Suzuki K., Sandhoff K., Vanier M. T. Molecular analysis of the acid sphingomyelinase deficiency in a family with an intermediate form of Niemann-Pick disease. Am J Hum Genet. 1995 Jun;56(6):1343–1349. [PMC free article] [PubMed] [Google Scholar]
  4. Helenius A., Marquardt T., Braakman I. The endoplasmic reticulum as a protein-folding compartment. Trends Cell Biol. 1992 Aug;2(8):227–231. doi: 10.1016/0962-8924(92)90309-b. [DOI] [PubMed] [Google Scholar]
  5. Henseler M., Klein A., Reber M., Vanier M. T., Landrieu P., Sandhoff K. Analysis of a splice-site mutation in the sap-precursor gene of a patient with metachromatic leukodystrophy. Am J Hum Genet. 1996 Jan;58(1):65–74. [PMC free article] [PubMed] [Google Scholar]
  6. Klausner R. D., Donaldson J. G., Lippincott-Schwartz J. Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol. 1992 Mar;116(5):1071–1080. doi: 10.1083/jcb.116.5.1071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Klima H., Klein A., van Echten G., Schwarzmann G., Suzuki K., Sandhoff K. Over-expression of a functionally active human GM2-activator protein in Escherichia coli. Biochem J. 1993 Jun 1;292(Pt 2):571–576. doi: 10.1042/bj2920571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Klima H., Tanaka A., Schnabel D., Nakano T., Schröder M., Suzuki K., Sandhoff K. Characterization of full-length cDNAs and the gene coding for the human GM2 activator protein. FEBS Lett. 1991 Sep 9;289(2):260–264. doi: 10.1016/0014-5793(91)81084-l. [DOI] [PubMed] [Google Scholar]
  9. Novak A., Lowden J. A. GM2 ganglioside activator occurs in multiple forms. Biochim Biophys Acta. 1994 Mar 2;1199(2):209–214. doi: 10.1016/0304-4165(94)90117-1. [DOI] [PubMed] [Google Scholar]
  10. Pelham H. R. Control of protein exit from the endoplasmic reticulum. Annu Rev Cell Biol. 1989;5:1–23. doi: 10.1146/annurev.cb.05.110189.000245. [DOI] [PubMed] [Google Scholar]
  11. Sanger F., Nicklen S., Coulson A. R. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A. 1977 Dec;74(12):5463–5467. doi: 10.1073/pnas.74.12.5463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Schnabel D., Schröder M., Fürst W., Klein A., Hurwitz R., Zenk T., Weber J., Harzer K., Paton B. C., Poulos A. Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. J Biol Chem. 1992 Feb 15;267(5):3312–3315. [PubMed] [Google Scholar]
  13. Schröder M., Schnabel D., Hurwitz R., Young E., Suzuki K., Sandhoff K. Molecular genetics of GM2-gangliosidosis AB variant: a novel mutation and expression in BHK cells. Hum Genet. 1993 Nov;92(5):437–440. doi: 10.1007/BF00216446. [DOI] [PubMed] [Google Scholar]
  14. Schwarzmann G. A simple and novel method for tritium labeling of gangliosides and other sphingolipids. Biochim Biophys Acta. 1978 Apr 28;529(1):106–114. doi: 10.1016/0005-2760(78)90108-x. [DOI] [PubMed] [Google Scholar]
  15. Schägger H., von Jagow G. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa. Anal Biochem. 1987 Nov 1;166(2):368–379. doi: 10.1016/0003-2697(87)90587-2. [DOI] [PubMed] [Google Scholar]
  16. Sonderfeld S., Conzelmann E., Schwarzmann G., Burg J., Hinrichs U., Sandhoff K. Incorporation and metabolism of ganglioside GM2 in skin fibroblasts from normal and GM2 gangliosidosis subjects. Eur J Biochem. 1985 Jun 3;149(2):247–255. doi: 10.1111/j.1432-1033.1985.tb08919.x. [DOI] [PubMed] [Google Scholar]
  17. Takahashi T., Suchi M., Desnick R. J., Takada G., Schuchman E. H. Identification and expression of five mutations in the human acid sphingomyelinase gene causing types A and B Niemann-Pick disease. Molecular evidence for genetic heterogeneity in the neuronopathic and non-neuronopathic forms. J Biol Chem. 1992 Jun 25;267(18):12552–12558. [PubMed] [Google Scholar]
  18. Xie B., Wang W., Mahuran D. J. A Cys138-to-Arg substitution in the GM2 activator protein is associated with the AB variant form of GM2 gangliosidosis. Am J Hum Genet. 1992 May;50(5):1046–1052. [PMC free article] [PubMed] [Google Scholar]

Articles from American Journal of Human Genetics are provided here courtesy of American Society of Human Genetics

RESOURCES